Skip to main content
Erschienen in: Malaria Journal 1/2020

Open Access 01.12.2020 | Research

Molecular surveillance and temporal monitoring of malaria parasites in focal Vietnamese provinces

verfasst von: Bui Van Long, Genevieve Allen, Melanie Brauny, Le Thi Kieu Linh, Srinivas Reddy Pallerla, Tran Thi Thu Huyen, Hoang Van Tong, Nguyen Linh Toan, Do Quyet, Ho Anh Son, Thirumalaisamy P. Velavan

Erschienen in: Malaria Journal | Ausgabe 1/2020

Abstract

Background

While the World Health Organization (WHO) Southeast Asia region has the second highest incidence of malaria worldwide, malaria in Vietnam is focal to few provinces, where delayed parasite clearance to anti-malarial drugs is documented. This study aims to understand Plasmodium species distribution and the genetic diversity of msp1 and msp2 of parasite populations using molecular tools.

Methods

A total of 222 clinical isolates from individuals with uncomplicated malaria were subjected to Plasmodium species identification by nested real-time PCR. 166 isolates positive for Plasmodium falciparum mono infections were further genotyped for msp1 (MAD20, K1, and RO33), and msp2 allelic families (3D7 and FC27). Amplicons were resolved through capillary electrophoresis in the QIAxcel Advanced system.

Results

Mono-infections were high and with 75% P. falciparum, 14% Plasmodium vivax and 9% P. falciparum/P. vivax co-infections, with less than 1% Plasmodium malariae identified. For msp1, MAD20 was the most prevalent (99%), followed by K1 (46%) allelic family, with no sample testing positive for RO33 (0%). For msp2, 3D7 allelic family was predominant (97%), followed by FC27 (10%). The multiplicity of infection of msp1 and msp2 was 2.6 and 1.1, respectively, and the mean overall multiplicity of infection was 3.7, with the total number of alleles ranging from 1 to 7.

Conclusions

Given the increasing importance of antimalarial drugs in the region, the genetic diversity of P. falciparum msp1 and msp2 should be regularly monitored with respect to treatment outcomes and/or efficacy studies in regions, where there are ongoing changes in the malaria epidemiology.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Background

Malaria is still one of the overwhelming public health problems worldwide, and the World Health Organization (WHO) Southeast Asia region has the second highest incidence of malaria with a total of 7.9 million cases in 2018 [1]. Although there are encouraging reports of declined malaria morbidity and mortality in Vietnam since last two decades [2], malaria prevalence in central and southern provinces is still high, in particular provinces bordering Laos and Cambodia [3]. Although 40 out of 63 provinces in Vietnam are declared malaria-free, only a few individual provinces contribute to a third of the cases in the country each year [3], with an additional 1600 imported cases contributing to the burden, a phenomenon first reported in 2018 [1].
In Vietnam, Plasmodium falciparum (64%) and Plasmodium vivax (35%) are the most important malaria parasites. Artemisinin-based combination therapy (ACT), especially using dihydroartemisinin piperaquine (DHA-PPQ), is the first-line of treatment [1]. One of the main obstacles to malaria control is the parasites’ ability to develop artemisinin resistance [4], which is inherently defined as delayed parasite clearance [5, 6]. Resistance to artemisinin is well documented in Vietnam, Western Cambodia and Thai-Myanmar borders [7]. Since a significant proportion of the Vietnamese population lives in malaria endemic areas, where resistant phenotypes have been reported, studies to decipher the genetic diversity and multiplicity of infections (MOI) of P. falciparum are essential to understand the intensity of transmission, epidemiological patterns and virulence of the parasites and, in particular, to evaluate measures aimed at malaria control [811].
The diversity of P. falciparum is usually determined by the evaluation of the extent of the polymorphism of the merozoite surface proteins msp1 and msp2, which are expressed on the surface of the merozoites during the erythrocytic stage of the life cycle of P. falciparum [12, 13]. The msp1 gene on chromosome 9 consists of 17 different blocks, and block 2 is highly polymorphic and consists of three different allelic families: MAD20, K1 and RO33. The msp2 gene on chromosome 2 contains highly polymorphic central repeats in block 3 and is distinguishable for two allelic families: 3D7 and FC27. Both msp1 and msp2 are highly immunogenic and are considered potential blood stage vaccine candidates [14, 15]. These two genetic markers are often used to indicate the number of parasitic strains present in a single host, which is useful in distinguishing between recrudescence and reinfection in drug efficacy studies [16]. The clonality of infection is the number of distinct clones/strain/genotypes per isolate (infected individual). More than one clone/genotype therefore implies polyclonality. Consequently, the mean number of genotypes or clones per infected individual (isolate) is defined to be the “multiplicity of infection” (MOI). A high MOI indicates that a single host carries multiple parasite strains and is associated with drug resistance of P. falciparum with excessive parasite transmission in holoendemic areas [16] .
In Vietnam, the predominant msp1 and msp2 alleles in 2012 [17] are MAD20 [18] and 3D7 [19], respectively. This study aims to determine the distribution of the Plasmodium species and subsequently the different msp1, msp2 genotypes and to estimate the MOI in clinical isolates from malaria endemic areas in Vietnam.

Methods

Study area and sampling

Written informed consent was obtained from all study participants. The study was approved by the Institutional Review Board of Vietnam Military Medical University, Hanoi, Vietnam. The study included 222 clinical isolates collected from adult individuals with uncomplicated malaria (mean age = 29.1 ± 9.5; 88% female). An individual who presents with symptoms of malaria and a positive parasitological test (microscopy or RDT) but with no features of severe malaria is defined as having uncomplicated malaria. Clinical isolates were collected in Vietnamese provinces, which included Dak Lak, Gia Lai and Dak Nong between years 2017–2019. The three provinces (Dak Lak, Gia Lai and Dak Nong) are adjacent to each other and are part of the central highlands bordering Cambodia. Whole blood samples were collected from individuals and were microscopically confirmed for the presence of Plasmodium parasites. Blood samples were stored at − 20 °C until further use.

Plasmodium species identification using nested real-time PCR

Genomic DNA was isolated from 50 µl whole blood using the QIAamp DNA Mini-Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. For detection and characterization of the Plasmodium species, a Taqman probe-based Pan-Plasmodium real-time PCR was used, as described earlier [20].
In short, the parasite DNA was amplified in a conventional PCR using the primers PLU5 and PLU6 [21]. The amplicons from the above PCR were used as templates in a single-plex nested real-time PCR assay for the differentiation of Plasmodium species. In each single-plex nested real-time PCR assay, distinct primers for P. falciparum [22], P. vivax [23], Plasmodium malariae, Plasmodium ovale curtisi, Plasmodium ovale wallikeri [20] are specifically used (Table 1). The assays were performed using SensiFAST™ Probe No-ROX Kit (Bioline, Tennessee, USA) in a LightCycler 480 Instrument II (Roche, Basel, Switzerland). Each clinical isolate was run in duplicates. The success of amplification is defined by respective Ct values that are smaller or equal to 40. All assays included a non-template control and positive control. The Ct values were calculated by default using the second derivative maximum method integrated in the LightCycler 480 software (version 1.5.1.62).
Table 1
List of primers used for plasmodium species identification using nested real-time PCR
Genus/species
Target
Primer ID
Primer sequence (5′ – 3′)
5′ modified
3′ modified
References
Plasmodium
18S rRNA gene
rPLU6-F
TTAAAATTGTTGCAGTTAAAACG
  
[21]
  
rPLU5-R
CCTGTTGTTGCCTTAAACTTC
   
P. falciparum
18S rRNA type S
PF-F
ATTGCTTTTGAGAGGTTTTGTTACTTT
  
[22]
  
PF-R
GCTGTAGTATTCAAACACAATGAACTCAA
   
  
PF-Probe
CATAACAGACGGGTAGTCAT
HEX
MGBEQ
 
P. vivax
18S rRNA type A
VIV-F
GCAACGCTTCTAGCTTAATCCAC
  
[23]
  
VIV-R
CAAGCCGAAGCAAAGAAAGTCC
   
  
VIV-Probe
ACTTTGTGCGCATTTTGCTA
HEX
MGBEQ
 
P. malariae
18S rRNA gene
PM-F
GGTGTTGGATGATAGAGTAA
  
[20]
  
PM-R
CCCAAAGACTTTGATTTCTC
   
  
PM-Probe
AGGAAGCTATCTAAAAGAAACACTCAT
HEX
BHQ-1
 
P. ovale curtisi
18S rRNA gene
POS-F
ATTTCAAAGAGTCATGGCGTTTCTG
  
[20]
  
POS-R
TTGTAAAGGAGACACTTTCTTGAAATCG
   
  
POS-Probe
CTCCTTGGTCGATCTGCCCAGCACT
FAM
BHQ-1
[20]
P. ovale wallikeri
18S rRNA gene
POS-F
ATTTCAAAGAGTCATGGCGTTTCTG
   
  
POW-R
TGTAAAGGAGACAACTTTCTTGGAGCTA
   
  
POW-Probe
TTGATCGCCCAGCACTGACCATCT
HEX
BHQ-1
 
HEX: 6-hexachlorofluorescein; FAM: 6-carboxyfluorescein; MGBEQ: minor groove binder eclipse quencher. BHQ-1: black hole quencher-1. rRNA: ribosomal ribonucleic acid

Plasmodium falciparum msp1 and msp2 genotyping

The samples positive for P. falciparum were genotyped by nested PCR. The outer PCR was used to amplify conserved regions of msp1 and msp2 and then the nested PCR was used to amplify MAD20, K1 and RO33 allele families at the msp1 gene locus and 3D7 and FC27 allele families at the msp2 gene locus. The outer and inner PCRs were performed with published primers as described elsewhere [24].
In brief: for the outer PCR, the DNA fragment was amplified in a reaction mixture of 20 µl volume containing 1x PCR buffer (20 mM Tris-HCl pH 8.4, 50 mM KCl, 1.5 mM MgCl2), 200 µM dNTPs, 100 nM of each primer and 1U Taq DNA polymerase (Qiagen, Hilden, Germany) on an Eppendorf Nexus Gradient PCR Cycler (Eppendorf, Hamburg, Germany). The thermal cycle parameters for the first PCR amplification were: initial denaturation at 94 °C for 10 min, followed by 35 cycles of 30 s at 94 °C denaturation, 30 s at 55 °C annealing, 1 min at 72 °C extension, followed by a final extension of 10 min at 72 °C. The inner PCRs for the allele families MAD20, K1 and RO33 (msp1) and 3D7 and FC27 (msp2) were performed with the outer PCR templates of msp1 and msp2, respectively. All five reactions were performed independently in 25 µl reaction mixture containing 3 µl from the outer PCR template, 1x PCR buffer, 1U Taq polymerase (Qiagen, Hilden, Germany), 200 µM dNTPs, 100 nM forward and reverse primers (Eurofins Genomic, Ebersberg, Germany). The PCR reaction conditions are identical to those of the outer PCR, except that the annealing temperature was 61 °C for the msp1 allele families and 56 °C for the msp2 allele families. For the msp1 positive controls, P. falciparum DNA was isolated from the strains Dd2, NF54 and 7G8 for the alleles MAD20, K1 and RO33, respectively. For the msp2 positive controls, DNA was isolated from P. falciparum strains Dd2 and NF54 for alleles 3D7 and FC27, respectively.
The QIAxcel Advanced system (Qiagen, Hilden, Germany) was used to resolve the amplicons by capillary electrophoresis. All nested PCR products were performed according to the AM420 protocol using the QX-DNA size marker 50–800 bp (Qiagen, Hilden, Germany) and the QX alignment marker 15 bp/1 kb (Qiagen, Hilden, Germany), except for the nested PCR products of the msp1 allele family K1. The nested K1 PCR products were performed using the AM420 protocol with the QX DNA size marker 100 bp − 2.5 kb (Qiagen, Hilden, Germany) and the QX alignment marker 15 bp/3 kb (Qiagen, Hilden, Germany).
The results were analysed with the QIAxcel Screen Gel software (Version 1.5.0.16, Qiagen, Hilden, Germany). All positive controls yielded a single peak, except the FC27 positive control, which clearly showed two peaks in each run (MAD20: 201, K1: 242 bp, RO33: 154 bp, 3D7: 237 bp, FC27: 469/623 bp). Each band represents one allele in the respective allele families (Fig. 1).

Multiplicity of infection (MOI)

The MOI was defined as the mean number of P. falciparum genotypes per infected individual. The MOI was calculated as a proportion of the total number of P. falciparum msp1 and msp2 genotypes and the total number of PCR positive isolates. Isolates with only one allele at each locus were considered single infections. Infections with more than one allele at one or more loci were considered polyclonal infections.

Results

Plasmodium species identification

On screening 222 samples, 166 (75%) isolates were positive for P. falciparum, 32 (14%) isolates were positive for P. vivax, one isolate was positive for P. malariae and 20 (9%) isolates were positive for both P. falciparum and P. vivax, indicating co-infection. Furthermore, we did not find any isolates positive for P. ovale curtisi and P. ovale wallikeri. In total, 3 (2%) of the isolates were PCR negative.

Genetic diversity and allelic frequency

All 166 isolates positive for P. falciparum by nested real-time PCR were subsequently genotyped for both msp1 and msp2 loci (Table 2). A total of 160 isolates were successfully amplified for msp1 and 153 isolates for msp2 loci, respectively. The MAD20 allelic family was predominant in 159 (99%) followed by K1 74 (46%) isolates, with the complete absence of RO33 allelic family. In msp1, 85 (53%) isolates were positive for MAD20 only and 73 (46%) isolates were positive for both MAD20 and K1, except one (0.6%) isolate that was positive for K1 only. In the msp2 locus the 3D7 allele family was predominant in 148 (97%) and the FC27 allele family in 16 (10%) isolates. A total of 137 (90%) isolates were positive for 3D7 and 11 (7%) positive for both 3D7 and FC27. There were up to 7 different alleles for msp1, with allele sizes varying between 141 and 255 bp (MAD20) and 161–1270 bp (K1). There were up to 4 different alleles for msp2, with allele sizes varying between 248 and 650 bp (3D7) and 366–531 bp (FC27).
Table 2
Distribution of msp1 and msp2 alleles
Alleles
Positive N (%)
msp1 (n = 160)
 MAD20 allelic family
159 (99%)
 K1 allelic family
74 (46%)
 RO33 allelic family
0 (0%)
 MAD20 + K1 (polyclonal)
73 (46%)
 MAD 20 (monoclonal)
85 (53%)
 K1 (monoclonal)
1 (0.6%)
 Mean MOI msp1 (± SD)
2.6 ± 1
msp2 (n = 153)
 3D7 allelic family
148 (97%)
 FC27 allelic family
16 (10%)
 3D7 + FC27 (polyclonal)
11 (7%)
 3D7 (monoclonal)
137 (90%)
 FC27 (monoclonal)
5 (3%)
 Mean MOI msp2 (± SD)
1.1 ± 0.5
 Overall MOI (msp1 + msp2)
3.7 ± 1.2

Multiplicity of infection (MOI)

Multiplicity of infection was calculated from the msp1 and msp2 genotyping results. A mean MOI of 2.6 ± 1 for msp1 and a mean MOI of 1.1 ± 0.5 for msp2, and an overall MOI for msp1 and msp2 is 3.7 ± 1.2 observed. There is no significant distribution of MOI between age groups.

Discussion

In this study, 222 clinical isolates were tested for Plasmodium species using sensitive real-time nested qPCR and were characterized the P. falciparum diversity, and MOI using molecular epidemiological tools.
From the nested real-time PCR results, 75% P. falciparum was observed, followed by 15% P. vivax and 8% P. falciparum/P. vivax co-infections. These results differ slightly from those of the WHO, where 64% was reported for P. falciparum and 35% for P. vivax in Vietnam [25]. These differences may be due to the fact that this study used a highly sensitive real-time PCR-based assay that is sensitive enough to detect submicroscopic infections. Another study showed that monitoring between December 2013 and January 2016 revealed 36% P. falciparum, 27% P. vivax, 25% co-infections with P. falciparum and P. vivax and 12% unidentified species from the same region [26]. In addition, it was reported that between 2006 and 2010, 70% of infections in Vietnam were due to P. falciparum. However, due to control measures, there has been a stronger impact on P. falciparum than on P. vivax since 2014, resulting in an almost equal ratio of both species [27]. Furthermore, co-infections with P. knowlesi and P. vivax have been documented in mosquitoes and humans in South Vietnam [28].
The use of ACT may have population-wide benefits in malaria control due to their effect in reducing the transfer of gametocytes, the sexual stage of the parasite, transmitted from humans to an Anopheles mosquito, during a blood meal [29, 30]. Rapid killing of the asexual parasite stages with artemisinin (99% daily killing rate) [29, 30] and, in combination with a partner drug, leads to a microscopically undetectable parasitaemia after 3 days of treatment [31]. Despite the decline of P. falciparum malaria in the last 10 years, and ACT being introduced as a component of comprehensive malaria control efforts, it is a challenge to reduce P. falciparum malaria cases in these provinces. The fact that the use of indoor spraying and insecticide-treated mosquito nets (ITN) is equally to contribute to these changes in the malaria epidemiology. Studies of the therapeutic efficacy of first-line treatment with DHA-PPQ at national sentinel sites have shown delayed parasite clearance in Gia Lai Province (2010), Dak Nong Province (2011), Quang Nam Province (2012), Khanh Hoa Province (2014) and Ninh Thuan Province (2015), with over 10% of patients being microscopically positive on day 3 after treatment initiation [32, 33].
Given the increasing importance of antimalarial drugs in the region, the genetic diversity of P. falciparum msp1 and msp2 should be regularly monitored with respect to treatment outcomes and/or efficacy studies in regions, where there are ongoing changes in the malaria epidemiology, as mentioned above [8, 9]. When magnified to understand the extent of parasite diversity in these provinces, the msp1 MAD20 allelic family (99%) and the msp2 3D7 allelic family was predominant (97%). These results are in accordance with an earlier study from Vietnam [17]. Another longitudinal study in the region, in Myanmar between 2004 and 2006 and 2013–2015 shows changes in the msp1 and msp2 allele distribution over time [19]. For example, the RO33 prevalence changed from 0% (2004–2006) to 21% (2013–2015). The RO33 allele appears to occur in low frequency in this geographical region, as also in Myanmar where the presence of this type in parasites is also rare [34, 35]. Nevertheless, MAD20 and 3D7 remained predominant for almost two decades [19].
Studies with multiplicity of infections (MOI) are rare in Vietnam. The overall MOI of msp1 and msp2 in this study was 2.6 and 1.1, respectively, and these differ from those in Thailand and Laos, which are geographically closer to Vietnam. For msp1, the MOI in Thailand and Laos are 1.7 and 1.6, respectively, and for msp2, the MOI in Thailand is 2.5 [36, 37]. These differences may be due to differences in transmission intensity, population and geographical areas. The investigations were performed with a QIAxcel Advanced system, compared to previously reported investigations performed with conventional slab gel electrophoresis. This automated sensitive, high-resolution capillary electrophoresis performed DNA fragment analysis with the QIAxcel ScreenGel software with a power to discriminate alleles with a 3–5 bp resolution.
Against the background of the increasing importance of resistance to antimalarial drugs, which is reported in the region, a low to moderate genetic diversity was observed in the focal endemic provinces in Vietnam based on the genetic diversity of P. falciparum msp1 and msp2. Routine monitoring of parasite genetic diversity has important implications for linking treatment outcomes and/or efficacy studies as the epidemiology of malaria changes.

Acknowledgements

The authors acknowledge the technical support from Mrs. Jutta Kun for the use of QIAExcel instrumentation.
Informed written consent was obtained from all study participants. The study was approved by the Institutional Review Board of Vietnam Military Medical University, Hanoi, Vietnam.
All authors have read and approved this submission. All authors have consented to publish this as an original article.

Competing interests

All authors disclose no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat WHO. World malaria report 2019. Geneva: World Health Organization; 2019. WHO. World malaria report 2019. Geneva: World Health Organization; 2019.
2.
Zurück zum Zitat Goldlust SM, Thuan PD, Giang DDH, Thang ND, Thwaites GE, Farrar J, et al. The decline of malaria in Vietnam, 1991–2014. Malar J. 2018;17:226.CrossRef Goldlust SM, Thuan PD, Giang DDH, Thang ND, Thwaites GE, Farrar J, et al. The decline of malaria in Vietnam, 1991–2014. Malar J. 2018;17:226.CrossRef
3.
Zurück zum Zitat Phuong NL. Viet Nam ready to eliminate malaria. Geneva: World Health Organization; 2018. Phuong NL. Viet Nam ready to eliminate malaria. Geneva: World Health Organization; 2018.
4.
Zurück zum Zitat Velavan TP, Nderu D, Agbenyega T, Ntoumi F, Kremsner PG. An alternative dogma on reduced artemisinin susceptibility: a new shadow from east to west. Proc Natl Acad Sci USA. 2019;116:12611–2.CrossRef Velavan TP, Nderu D, Agbenyega T, Ntoumi F, Kremsner PG. An alternative dogma on reduced artemisinin susceptibility: a new shadow from east to west. Proc Natl Acad Sci USA. 2019;116:12611–2.CrossRef
5.
Zurück zum Zitat Kremsner PG, Adegnika AA, Hounkpatin AB, Zinsou JF, Taylor TE, Chimalizeni Y, et al. Intramuscular artesunate for severe malaria in African children: a multicenter randomized controlled trial. PLoS Med. 2016;13:e1001938.CrossRef Kremsner PG, Adegnika AA, Hounkpatin AB, Zinsou JF, Taylor TE, Chimalizeni Y, et al. Intramuscular artesunate for severe malaria in African children: a multicenter randomized controlled trial. PLoS Med. 2016;13:e1001938.CrossRef
6.
Zurück zum Zitat Krishna S, Staines HM, Kremsner PG. Artemisinin resistance and the blame game. Clin Infect Dis. 2016;63:1144–5.CrossRef Krishna S, Staines HM, Kremsner PG. Artemisinin resistance and the blame game. Clin Infect Dis. 2016;63:1144–5.CrossRef
7.
Zurück zum Zitat Nguetse CN, Adegnika AA, Agbenyega T, Ogutu BR, Krishna S, Kremsner PG, et al. Molecular markers of anti-malarial drug resistance in Central, West and East African children with severe malaria. Malar J. 2017;16:217.CrossRef Nguetse CN, Adegnika AA, Agbenyega T, Ogutu BR, Krishna S, Kremsner PG, et al. Molecular markers of anti-malarial drug resistance in Central, West and East African children with severe malaria. Malar J. 2017;16:217.CrossRef
8.
Zurück zum Zitat Zhong D, Lo E, Wang X, Yewhalaw D, Zhou G, Atieli HE, et al. Multiplicity and molecular epidemiology of Plasmodium vivax and Plasmodium falciparum infections in East Africa. Malar J. 2018;17:185.CrossRef Zhong D, Lo E, Wang X, Yewhalaw D, Zhou G, Atieli HE, et al. Multiplicity and molecular epidemiology of Plasmodium vivax and Plasmodium falciparum infections in East Africa. Malar J. 2018;17:185.CrossRef
9.
Zurück zum Zitat Some AF, Bazie T, Zongo I, Yerbanga RS, Nikiema F, Neya C, et al. Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso. Parasit Vectors. 2018;11:323.CrossRef Some AF, Bazie T, Zongo I, Yerbanga RS, Nikiema F, Neya C, et al. Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso. Parasit Vectors. 2018;11:323.CrossRef
10.
Zurück zum Zitat Mahdi Abdel Hamid M, Elamin AF, Albsheer MM, Abdalla AA, Mahgoub NS, Mustafa SO, et al. Multiplicity of infection and genetic diversity of Plasmodium falciparum isolates from patients with uncomplicated and severe malaria in Gezira State, Sudan. Parasit Vectors. 2016;9:362.CrossRef Mahdi Abdel Hamid M, Elamin AF, Albsheer MM, Abdalla AA, Mahgoub NS, Mustafa SO, et al. Multiplicity of infection and genetic diversity of Plasmodium falciparum isolates from patients with uncomplicated and severe malaria in Gezira State, Sudan. Parasit Vectors. 2016;9:362.CrossRef
11.
Zurück zum Zitat Nguetse CN, Ojo JA, Nchotebah C, Ikegbunam MN, Meyer CG, Thomas BN, et al. Genetic diversity of the Plasmodium falciparum glutamate-rich protein r2 region before and twelve years after introduction of artemisinin combination therapies among febrile children in Nigeria. Am J Trop Med Hyg. 2018;98:667–76.CrossRef Nguetse CN, Ojo JA, Nchotebah C, Ikegbunam MN, Meyer CG, Thomas BN, et al. Genetic diversity of the Plasmodium falciparum glutamate-rich protein r2 region before and twelve years after introduction of artemisinin combination therapies among febrile children in Nigeria. Am J Trop Med Hyg. 2018;98:667–76.CrossRef
12.
Zurück zum Zitat Takala SL, Escalante AA, Branch OH, Kariuki S, Biswas S, Chaiyaroj SC, et al. Genetic diversity in the Block 2 region of the merozoite surface protein 1 (MSP-1) of Plasmodium falciparum: additional complexity and selection and convergence in fragment size polymorphism. Infect Genet Evol. 2006;6:417–24.CrossRef Takala SL, Escalante AA, Branch OH, Kariuki S, Biswas S, Chaiyaroj SC, et al. Genetic diversity in the Block 2 region of the merozoite surface protein 1 (MSP-1) of Plasmodium falciparum: additional complexity and selection and convergence in fragment size polymorphism. Infect Genet Evol. 2006;6:417–24.CrossRef
13.
Zurück zum Zitat Apinjoh TO, Tata RB, Anchang-Kimbi JK, Chi HF, Fon EM, Mugri RN, et al. Plasmodium falciparum merozoite surface protein 1 block 2 gene polymorphism in field isolates along the slope of mount Cameroon: a cross - sectional study. BMC Infect Dis. 2015;15:309.CrossRef Apinjoh TO, Tata RB, Anchang-Kimbi JK, Chi HF, Fon EM, Mugri RN, et al. Plasmodium falciparum merozoite surface protein 1 block 2 gene polymorphism in field isolates along the slope of mount Cameroon: a cross - sectional study. BMC Infect Dis. 2015;15:309.CrossRef
14.
Zurück zum Zitat Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis. 2002;185:820–7.CrossRef Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis. 2002;185:820–7.CrossRef
15.
Zurück zum Zitat McCarthy JS, Marjason J, Elliott S, Fahey P, Bang G, Malkin E, et al. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide(R) ISA 720. PLoS One. 2011;6:e24413.CrossRef McCarthy JS, Marjason J, Elliott S, Fahey P, Bang G, Malkin E, et al. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide(R) ISA 720. PLoS One. 2011;6:e24413.CrossRef
16.
Zurück zum Zitat Mombo-Ngoma G, Remppis J, Sievers M, Zoleko Manego R, Endamne L, et al. Efficacy and safety of fosmidomycin-piperaquine as nonartemisinin-based combination therapy for uncomplicated falciparum malaria: a single-arm, age de-escalation proof-of-concept study in Gabon. Clin Infect Dis. 2018;66:1823–30.CrossRef Mombo-Ngoma G, Remppis J, Sievers M, Zoleko Manego R, Endamne L, et al. Efficacy and safety of fosmidomycin-piperaquine as nonartemisinin-based combination therapy for uncomplicated falciparum malaria: a single-arm, age de-escalation proof-of-concept study in Gabon. Clin Infect Dis. 2018;66:1823–30.CrossRef
17.
Zurück zum Zitat Aspeling-Jones H, Conway DJ. An expanded global inventory of allelic variation in the most extremely polymorphic region of Plasmodium falciparum merozoite surface protein 1 provided by short read sequence data. Malar J. 2018;17:345.CrossRef Aspeling-Jones H, Conway DJ. An expanded global inventory of allelic variation in the most extremely polymorphic region of Plasmodium falciparum merozoite surface protein 1 provided by short read sequence data. Malar J. 2018;17:345.CrossRef
18.
Zurück zum Zitat Ferreira MU, Liu Q, Zhou M, Kimura M, Kaneko O, Van Thien H, et al. Stable patterns of allelic diversity at themerozoite surface protein-1 locus of Plasmodium falciparum in clinical isolates from southern Vietnam. J Eukaryot Microbiol. 1998;45:131–6.CrossRef Ferreira MU, Liu Q, Zhou M, Kimura M, Kaneko O, Van Thien H, et al. Stable patterns of allelic diversity at themerozoite surface protein-1 locus of Plasmodium falciparum in clinical isolates from southern Vietnam. J Eukaryot Microbiol. 1998;45:131–6.CrossRef
19.
Zurück zum Zitat Le HG, Kang JM, Jun H, Lee J, Thai TL, Myint MK, et al. Changing pattern of the genetic diversities of Plasmodium falciparum merozoite surface protein-1 and merozoite surface protein-2 in Myanmar isolates. Malar J. 2019;8:241.CrossRef Le HG, Kang JM, Jun H, Lee J, Thai TL, Myint MK, et al. Changing pattern of the genetic diversities of Plasmodium falciparum merozoite surface protein-1 and merozoite surface protein-2 in Myanmar isolates. Malar J. 2019;8:241.CrossRef
20.
Zurück zum Zitat Groger M, Veletzky L, Lalremruata A, Cattaneo C, Mischlinger J, Zoleko-Manego R, et al. Prospective clinical trial assessing species-specific efficacy of artemether-lumefantrine for the treatment of Plasmodium malariae, Plasmodium ovale, and mixed Plasmodium malaria in Gabon. Antimicrob Agents Chemother. 2018;62:e01758-17.CrossRef Groger M, Veletzky L, Lalremruata A, Cattaneo C, Mischlinger J, Zoleko-Manego R, et al. Prospective clinical trial assessing species-specific efficacy of artemether-lumefantrine for the treatment of Plasmodium malariae, Plasmodium ovale, and mixed Plasmodium malaria in Gabon. Antimicrob Agents Chemother. 2018;62:e01758-17.CrossRef
21.
Zurück zum Zitat Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, et al. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol. 1993;61:315–20.CrossRef Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, et al. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol. 1993;61:315–20.CrossRef
22.
Zurück zum Zitat Veron V, Legrand E, Yrinesi J, Volney B, Simon S, Carme B. Genetic diversity of msp3alpha and msp1_b5 markers of Plasmodium vivax in French Guiana. Malar J. 2009;8:40.CrossRef Veron V, Legrand E, Yrinesi J, Volney B, Simon S, Carme B. Genetic diversity of msp3alpha and msp1_b5 markers of Plasmodium vivax in French Guiana. Malar J. 2009;8:40.CrossRef
23.
Zurück zum Zitat Kamau E, Alemayehu S, Feghali KC, Saunders D, Ockenhouse CF. Multiplex qPCR for detection and absolute quantification of malaria. PLoS ONE. 2013;8:e71539.CrossRef Kamau E, Alemayehu S, Feghali KC, Saunders D, Ockenhouse CF. Multiplex qPCR for detection and absolute quantification of malaria. PLoS ONE. 2013;8:e71539.CrossRef
24.
Zurück zum Zitat Atroosh WM, Al-Mekhlafi HM, Mahdy MA, Saif-Ali R, Al-Mekhlafi AM, Surin J. Genetic diversity of Plasmodium falciparum isolates from Pahang, Malaysia based on MSP-1 and MSP-2 genes. Parasit Vectors. 2011;4:233.CrossRef Atroosh WM, Al-Mekhlafi HM, Mahdy MA, Saif-Ali R, Al-Mekhlafi AM, Surin J. Genetic diversity of Plasmodium falciparum isolates from Pahang, Malaysia based on MSP-1 and MSP-2 genes. Parasit Vectors. 2011;4:233.CrossRef
25.
Zurück zum Zitat WHO. Malaria Country Profiles Viet Nam. Geneva: World Health Organization; 2018. WHO. Malaria Country Profiles Viet Nam. Geneva: World Health Organization; 2018.
26.
Zurück zum Zitat Nguyen TN, von Seidlein L, Nguyen TV, Truong PN, Hung SD, Pham HT, et al. The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in Vietnam: an open cohort study. Lancet Infect Dis. 2018;18:565–72.CrossRef Nguyen TN, von Seidlein L, Nguyen TV, Truong PN, Hung SD, Pham HT, et al. The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in Vietnam: an open cohort study. Lancet Infect Dis. 2018;18:565–72.CrossRef
27.
Zurück zum Zitat Kattenberg JH, Erhart A, Truong MH, Rovira-Vallbona E, Vu KAD, Nguyen THN, et al. Characterization of Plasmodium falciparum and Plasmodium vivax recent exposure in an area of significantly decreased transmission intensity in Central Vietnam. Malar J. 2018;17:180.CrossRef Kattenberg JH, Erhart A, Truong MH, Rovira-Vallbona E, Vu KAD, Nguyen THN, et al. Characterization of Plasmodium falciparum and Plasmodium vivax recent exposure in an area of significantly decreased transmission intensity in Central Vietnam. Malar J. 2018;17:180.CrossRef
28.
Zurück zum Zitat Marchand RP, Culleton R, Maeno Y, Quang NT, Nakazawa S. Co-infections of Plasmodium knowlesi, P. falciparum, and P. vivax among humans and Anopheles dirus mosquitoes, Southern Vietnam. Emerg Infect Dis. 2011;17:1232–9.CrossRef Marchand RP, Culleton R, Maeno Y, Quang NT, Nakazawa S. Co-infections of Plasmodium knowlesi, P. falciparum, and P. vivax among humans and Anopheles dirus mosquitoes, Southern Vietnam. Emerg Infect Dis. 2011;17:1232–9.CrossRef
29.
Zurück zum Zitat Targett G, Drakeley C, Jawara M, von Seidlein L, Coleman R, Deen J, et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis. 2001;183:1254–9.CrossRef Targett G, Drakeley C, Jawara M, von Seidlein L, Coleman R, Deen J, et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis. 2001;183:1254–9.CrossRef
30.
Zurück zum Zitat Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R, et al. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis. 2006;193:1151–9.CrossRef Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R, et al. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis. 2006;193:1151–9.CrossRef
31.
Zurück zum Zitat White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320:330–4.CrossRef White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320:330–4.CrossRef
32.
Zurück zum Zitat Phong NC, Chavchich M, Quang HH, San NN, Birrell GW, Chuang I, et al. Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam. Malar J. 2019;18:10.CrossRef Phong NC, Chavchich M, Quang HH, San NN, Birrell GW, Chuang I, et al. Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam. Malar J. 2019;18:10.CrossRef
33.
Zurück zum Zitat Thanh NV, Thuy-Nhien N, Tuyen NT, Tong NT, Nha-Ca NT, Dong LT, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam. Malar J. 2017;16:27.CrossRef Thanh NV, Thuy-Nhien N, Tuyen NT, Tong NT, Nha-Ca NT, Dong LT, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam. Malar J. 2017;16:27.CrossRef
34.
Zurück zum Zitat Kang JM, Moon SU, Kim JY, Cho SH, Lin K, Sohn WM, et al. Genetic polymorphism of merozoite surface protein-1 and merozoite surface protein-2 in Plasmodium falciparum field isolates from Myanmar. Malar J. 2010;9:131.CrossRef Kang JM, Moon SU, Kim JY, Cho SH, Lin K, Sohn WM, et al. Genetic polymorphism of merozoite surface protein-1 and merozoite surface protein-2 in Plasmodium falciparum field isolates from Myanmar. Malar J. 2010;9:131.CrossRef
35.
Zurück zum Zitat Soe TN, Wu Y, Tun MW, Xu X, Hu Y, Ruan Y, et al. Genetic diversity of Plasmodium falciparum populations in southeast and western Myanmar. Parasit Vectors. 2017;10:322.CrossRef Soe TN, Wu Y, Tun MW, Xu X, Hu Y, Ruan Y, et al. Genetic diversity of Plasmodium falciparum populations in southeast and western Myanmar. Parasit Vectors. 2017;10:322.CrossRef
36.
Zurück zum Zitat Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, Brown KN, et al. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg. 1999;93:369–74.CrossRef Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, Brown KN, et al. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg. 1999;93:369–74.CrossRef
37.
Zurück zum Zitat Khaminsou N, Kritpetcharat O, Daduang J, Charerntanyarak L, Kritpetcharat P. Genetic analysis of the merozoite surface protein-1 block 2 allelic types in Plasmodium falciparum clinical isolates from Lao PDR. Malar J. 2011;10:371.CrossRef Khaminsou N, Kritpetcharat O, Daduang J, Charerntanyarak L, Kritpetcharat P. Genetic analysis of the merozoite surface protein-1 block 2 allelic types in Plasmodium falciparum clinical isolates from Lao PDR. Malar J. 2011;10:371.CrossRef
Metadaten
Titel
Molecular surveillance and temporal monitoring of malaria parasites in focal Vietnamese provinces
verfasst von
Bui Van Long
Genevieve Allen
Melanie Brauny
Le Thi Kieu Linh
Srinivas Reddy Pallerla
Tran Thi Thu Huyen
Hoang Van Tong
Nguyen Linh Toan
Do Quyet
Ho Anh Son
Thirumalaisamy P. Velavan
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
Malaria Journal / Ausgabe 1/2020
Elektronische ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-020-03561-6

Weitere Artikel der Ausgabe 1/2020

Malaria Journal 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.